Therapeutic effects of survivin and bcl-2 gene combined with antisense oligodeoxynucleotide on human breast cancer transplanted subcutaneously in nude mice

Abstract

Abstract: AIM: To investigate the effects of surviving and bcl-2 combined with ASODN on the treatment of breast cancer xenograft in nude mice.METHODS: The model of xenografts derived from MCF-7 breast cancer cell was established in BALB/c nude mice , then they were randomly divided into a negative control grouPand 5 experimental groups [intraperitoneal injection of liposomesurvivin-SODN , liposome-bcl-2-SODN , liposome-survivin-ASODN , liposome-bcl-2-ASODN , combined ASODN].The tumor growth inhibitory rate and the tumor volume decreased rate were calculated.RESULTS: Survivin and bcl-2 combined with ASODN exhibited potent tumor growth inhibition.The tumor volume inhibitory rate was 78.4%;the tumor weight inhibitory rate was 75.3%;the tumor volume decreased rate was 41.6%for combined grouPpost-experiment of the 6 groups , and there was no significant difference on nude mice weight post-experiment.CONCLUSION: Survivin and bcl-2 combined with ASODN showed potent tumor growth inhibition in vivo.

Key words: antisense oligodeoxynucleotide, surviving, bcl-2, breast cancer, xenograft

CLC Number:

R965.2
R966

WANG Wen-wu, OU-YANG Xue-nong, ZHANG Xia, JIANG Hao. Therapeutic effects of survivin and bcl-2 gene combined with antisense oligodeoxynucleotide on human breast cancer transplanted subcutaneously in nude mice[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(10): 1164-1167.

References

1 Kronenwell R, Hass R.Antisense strategies for the treatment of hematological malignancies and solid tumors[J].Ann Hematol,1998;77:1-12
2 Guha C, Guha U, Tribius S, Alfieri A, Casper D, Chakravarty P, et al.Antisense ATM gene therapy:a strategy to increase the radiosensitivity of human tumor[J].Gene Ther , 2000;7:852-8
3 Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK,Heldin CH, Rubin K.Inhibition of platelet-derived Growth Factor Receptor reduces interstitial hypertension and increase transcapillary in tumor[J].Cancer Res, 2001;61:2929-34
4 王颖, 王家龙.生存素反义寡核酸诱导肝癌细胞凋亡的实验研究[J].中华消化杂志, 2003;23:11-4
5 苏逢锡, 陈积圣, 贾卫娟, 宋尔卫.bcl-2 基因表达与乳腺癌抗凋亡及免疫耐受的关系[J].中华普通外科杂志,2001;16:549-51
6 沈梅, 丰有吉, 周先荣.脂质体c-erbB-2 反义寡核苷酸对人卵巢上皮癌裸鼠皮下移植瘤的治疗作用[J].现代妇科进展, 1998;7:314-6
7 Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N.Expression of survivin and its relationshiPto loss of apoptosis in breast carcinomas[J].Clin Cancer Res, 2000;6:127-34
8 Bilim V, Kasahara T, Noboru H, Takahashi K, Tomita Y.Caspase involved synergistic cytotoxicity of bcl-2 antisense oligonucleotides and adriamy cin on transitional cell cancer cells[J].Cancer lett , 2000 , 155:191-8
9 Bloem A, Lockhorst H.Bcl-2 antisense therapy in multiple myeloma[J].Pathol Biol , 1999;47:216-20
10 Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Alt-Chin J Clin Pharmacol Ther 2006 Oct;11(10)ieri DC.Therapeutic targeting of the survivin pathway in cancer:initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis[J]. Ther 2006 Oct;11(10)ieri DC.Therapeutic targeting of the survivin pathway in cancer:initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis[J].Clin Cancer Res, 2003;9:2683-92
11 Choi KS, Lee TH, Jung MH.Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells[J].Cancer Gene Ther , 2003;10:87-95
12 Marcusson EG, Yacy shyn BR, Shanahan WR Jr, Dean NM.Preclinical and clinical pharmacology of antisense oligonucleotides[J].Mol Biotechnol, 1999;12:1-11
13 Kim CK, Haider KhH, Choi SH.Nonviral vector for efficient gene transfer to human overian adenocarcinoma cells[J].Gynecol Oncol , 2002;84:85-93

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[3]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[4]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[5]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[6]	CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing. Clinical application and research progress of antibody drugs conjugation in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
[7]	LI Mengxi, ZHANG Kejing, XIA Fan. Research progress in vaccine for breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925.
[8]	WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
[9]	WANG Xiu, JI Qilin, PEI Wenjun, ZENG Ying. 3-bromopyruvate cholesterol ester enhances the sensitivity of breast cancer cells to tamoxifen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1093-1100.
[10]	WU Shuai, YANG Jun, ZHENG Yun. Dual role of miRNA in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 814-821.
[11]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
[12]	DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
[13]	YAO Yao, XIA Min, HOU Cong, HE Airong. Effects of ABT-737 on the growth and angiogenesis of ovarian cancer cells in the co-culture of TAMs and SKOV3 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 144-153.
[14]	XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi. Population pharmacokinetics of capecitabine in Chinese breast cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
[15]	SUN Hong, HOU Jialin, CAI Jiaqin, WEI Xiaoxia, ZHUANG Jie. SUMO E3 ligase mediates androgen receptor transcription to promote tamoxifen resistance of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 285-291.